PennyStockPayCheck.com Rss

Featured Posts

Chase Bank Limits Cash Withdrawals, Bans International... Before you read this report, remember to sign up to http://pennystockpaycheck.com for 100% free stock alerts Chase Bank has moved to limit cash withdrawals while banning business customers from sending...

Read more

Richemont chairman Johann Rupert to take 'grey gap... Billionaire 62-year-old to take 12 months off from Cartier and Montblanc luxury goods groupRichemont's chairman and founder Johann Rupert is to take a year off from September, leaving management of the...

Read more

Cambodia: aftermath of fatal shoe factory collapse... Workers clear rubble following the collapse of a shoe factory in Kampong Speu, Cambodia, on Thursday

Read more

Spate of recent shock departures by 50-something CEOs While the rising financial rewards of running a modern multinational have been well publicised, executive recruiters say the pressures of the job have also been ratcheted upOn approaching his 60th birthday...

Read more

UK Uncut loses legal challenge over Goldman Sachs tax... While judge agreed the deal was 'not a glorious episode in the history of the Revenue', he ruled it was not unlawfulCampaign group UK Uncut Legal Action has lost its high court challenge over the legality...

Read more

Amarin Prescription Fish-Oil Pill Approved

Category : Stocks

Updated with new information.

BEDMINSTER, NJ (TheStreet) –The U.S. Food and Drug Administration on Thursday approved a prescription fish-oil pill from Amarin that will be used to treat patients with very high levels of triglycerides, a type of fat found in blood.

Amarin’s newly approved drug Vascepa is made from ultra-purified ethyl EPA, an omega-3 fatty acid commonly found in fish. An FDA spokesperson confirmed the approval. …

Click to view a price quote on AMRN.

Click to research the Drugs industry.

More here: Amarin Prescription Fish-Oil Pill Approved

Post to Twitter

DaVita Settles Lawsuit for $55 Million

Category : Business

NEW YORK (TheStreet) — DaVita Inc. announced Tuesday it has settled a lawsuit over its use of an anemia medication for $55 million.

Filed 10 years ago in a federal court in Texas, the lawsuit was based on one person’s claim that the dialysis service provider overused Epogen, an anemia drug.

In a news release about the settlement, The Denver-based company said it and its physicians did nothing wrong and “stand by” their anemia management practices. …

Click to view a price quote on DVA.

Click to research the Health Services industry.

Read more: DaVita Settles Lawsuit for $55 Million

Post to Twitter

Arena Pharma And The Fat Lady’s Song

Category : Stocks

Updated with current stock price.

NEW YORK (TheStreet) — Last month, Arena Pharmaceuticals received a positive vote from the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee for the use of lorcaserin to treat obesity. The company did an admirable job parrying panelists’ questions and the FDA’s skepticism and earned an 18-to-4 recommendation for approval, with one abstention. On Wednesday, Arena faces its next hurdle: the Prescription Drug User Fee Act (PDUFA) date for lorcaserin, better known as the FDA’s approval decision date for the obesity drug.

Lorcaserin might receive final approval this week, but I think a three-month delay or another complete response letter (CRL) is more likely. As I have said in the past, I expect the FDA will require a Risk Evaluation and Mitigation Strategy (REMS) to minimize inappropriate use of the drug and the risk of an unexpected safety debacle. (The sting of repeated obesity drug fiascos — American Home Products’ fenfluramine-phentermine, known as Fen-phen, and Abbott’s Meridia in the U.Ss, and Sanofi’s rimonabant in Europe — won’t go away any time soon.) Ultimately though, I think lorcaserin will be approved for sale in the US (and probably Europe, although a decision from European regulators won’t come until early-to-mid 2013). …

Click to view a price quote on ARNA.

Click to research the Drugs industry.

Link: Arena Pharma And The Fat Lady’s Song

Post to Twitter

Cramer’s ‘Mad Money’ Recap: Cramer’s Game Plan

Category : Stocks

Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.

NEW YORK (TheStreet) — Special situations will dominate next week’s trading, Jim Cramer told “Mad Money” viewers Friday as he laid out his game plan. Cramer said next week may be the week Europe gets its act together, but don’t count on it. …

Click to view a price quote on JACK.

Click to research the Leisure industry.

See the original post here: Cramer’s ‘Mad Money’ Recap: Cramer’s Game Plan

Post to Twitter

Healthcare Changed Before Obamacare Supreme Court Ruling

Category : Business, Stocks

Updated to reflect Walgreens part-owner comment and Jefferies analysis

NEW YORK (TheStreet) – It’s no secret that the Supreme Court’s looming decision on President Obama’s Affordable Care Act looms large over the healthcare stocks. Still, investors may wise to spend their time understanding how consolidation is already reshaping the healthcare sector ahead of the June decision.

The Supreme Court will decide whether or not Medicaid is expanded, potentially having biggest impact on Medicaid HMO’s like Amerigroup, Molina and Centene. Diversified healthcare providers like Aetna, Cigna, like UnitedHealthcare and Coventry will also be watching. Forget the SCOTUS decision, the market has already changed for healthcare stocks …

Click to view a price quote on WAG.

Click to research the Retail industry.

Follow this link: Healthcare Changed Before Obamacare Supreme Court Ruling

Post to Twitter

Cramer’s ‘Mad Money’ Recap: Putting Europe Into Perspective

Category : Business

Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.

NEW YORK (TheStreet) — Let’s keep one eye on Europe but the other on America, Jim Cramer told “Mad Money” viewers Monday as he tried to put the European crisis into perspective for investors. …

Click to view a price quote on SBUX.

Click to research the Leisure industry.

The rest is here: Cramer’s ‘Mad Money’ Recap: Putting Europe Into Perspective

Post to Twitter

Johnson & Johnson’s Synthes Deal Revives Foreign Tax Debate

Category : Business, Stocks

NEW YORK (TheStreet) — To make the largest deal in its 126-year history an earnings boost, Johnson & Johnson is keeping its acquisition of Synthes as far as from the U.S. taxman as possible.

After receiving regulatory clearance for its $19.7 billion acquisition of Swiss medical device maker Synthes, Johnson & Johnson says the mega-deal will add to earnings per share after previously forecasting dilution: All with the help of bankers JPMorgan Chase and Goldman Sachs. …

Click to view a price quote on JNJ.

Click to research the Drugs industry.

Read more: Johnson & Johnson’s Synthes Deal Revives Foreign Tax Debate

Post to Twitter

Auxilium On a Roll with Xiaflex, Testim Deal

Category : Stocks

Adrian Adams, CEO of Auxilium, discusses the company’s breakthrough with Xiaflex, as well as recent news surrounding its drug Testim.

View post: Auxilium On a Roll with Xiaflex, Testim Deal

Post to Twitter

Cramer’s ‘Mad Money’ Recap: Facing a Worst-Case Scenario

Category : Business

Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.

NEW YORK (TheStreet) — Investors need a game plan to deal with worst-case scenarios, Jim Cramer warned “Mad Money” viewers Monday. But what exactly is the worst case? Cramer laid it all on the line in plain English. …

Click to view a price quote on IMGN.

Click to research the Drugs industry.

See the article here: Cramer’s ‘Mad Money’ Recap: Facing a Worst-Case Scenario

Post to Twitter

ASCO ’12: Roche, ImmunoGen Drug Delays Breast Tumor Growth

Category : Business, Stocks

CHICAGO (TheStreet) — An experimental antibody-drug conjugate therapy from the Genentech unit of Roche delayed by more than three months the re-growth of breast cancer compared to the current standard of care, according to a phase III study being presented today at the American Society of Clinical Oncology (ASCO) annual meeting.

The drug, known as T-DM1, will be filed for regulatory approval in the U.S. and Europe later this year, Roche said.

T-DM1 is a second-generation version of Genentech’s blockbuster breast cancer drug Herceptin. The drug consists of Herceptin (also known as trastuzumab) linked to a tumor-killing chemotherapy payload developed by ImmunoGen. …

Click to view a price quote on RHHBY.

See the original post here: ASCO ’12: Roche, ImmunoGen Drug Delays Breast Tumor Growth

Post to Twitter